Gyrus Medical, Cardiff, UK 510(k) Premarket Notification
11 May 2004 SEP 1 0 2004 Gyrus G3 Generator System & Accessories
K 041295 ((24e § 2G
510(k) Summary of Safety and Effectiveness a
Gyrus G3 System (Generator & Accessories)
Submitted by: Gyrus Medical Ltd
Fortran Road
St Mellons,
Cardiff CF30LT
UK
Contact Person: Andrew Dzimitrowicz
Quality Manager
Telephone: +44 29 20 776 349
Facsimile: +44 29 20 776 591
Date Summary Prepared: 11" May 2004
Name of the Device:
Proprietary Name: Gyrus G3 System (Generator & Accessories)
Project Name: G3
Common/Usual Name: Electrosurgical Generator and Accessories
Classification Name: Electrosurgical Cutting & Coagulation Device and
Accessories (per 21 CFR 878.4400)
Brand Name: Not yet assigned
Predicate Devices: K021777 (G2 Radio-frequency Workstation &
Accessories)

| toy & LQ

Gyrus Medical, Cardiff, UK 510(k) Premarket Notification

11 May 2004 Gyrus G3 Generator System & Accessories

Description: The Gyrus G3 System Generator has two principal
modes of operation:

- The monopolar mode has conirols for maximum
temperature and energy delivered. The unit has
readouts for total energy delivered, impedance,
temperature for two thermocouples and time of
energy delivery.

- The bipolar mode has controls for output waveform
type and power. The unit has readouts for set power
and waveform.

Connectors on the front panel include the monopolar

connector for active electrode and dispersive electrode

and separate dual bipolar connectors for PlasmaCision
electrodes and bipolar instruments. The foot pedal is
connected on the back panel.

Accessories included with the generator are the

electrodes, connector cable, footswitch and a power

cable.

Statement of Intended Use: The Gyrus G3 System is intended for use for ablation,
resection and coagulation of soft tissue and hemostasis
of blood vessels in otorhinolaryngology (Head and Neck)
surgery coagulation of soft tissue.

~ This device is intended for use by qualified medical
personnel trained in the use of electrosurgery.

Comparison to Predicate Devices: The Gyrus G3 System has been carefully compared to
legally marketed devices with respect to intended use
and technological characteristics. In addition,
performance testing has been done to validate the
performance of the device. The comparison and
validation results presented in this 510(k) notification to
the FDA show that the device is substantially equivalent
to predicate devices and is safe and effective in its
intended use.

iG

ey
f DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
% &
“om Food and Drug Administration
SEP 10 2008 Roewile MD 20850
Mr. Andrew Dzimitrowicz
Director of RA/QA
Gyrus Medical Ltd.
Fortran Road, St. Mellons
Cardiff
United Kingdom CF3 OLT
Re: K041285
Trade/Device Name: Gyrus G3 Radio-Frequency Workstation and Accessories .
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: II
Product Code: GEI
Dated: July 13, 2004
Received: July 16, 2004
Dear Mr. Dzimitrowicz:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CER Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Andrew Dzimitrowicz
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
“Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

py Nema 0 Bovoat

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative

and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

| i
Gyrus Medical, Cardiff, UK $10(k} Premarket Notification
11 May 2004 Gyrus G3 Generator System & Accessories
Indications for Use :
510(k) Number (if known): Nat Yet Assigned bt O4IQSS
Device Name: Gyrus G3 Radio-frequency workstation & Accessories
Indications For Use:
The Bipolar Generator section of the G3 RF Workstation is indicated for ablation, resection and
coagulation of soft tissue and hemostasis of blood vessels in otorhinolaryngology (Head and Neck}
surgery including:
*  Adenoidectomy s___Papilloma Keloids
+ Cysts © Subiiicesal Palatal Shrinkage
. Head, Neck, Oral, and Sinus Surgery * — Tonsillectomy
. Mastoidectomy * — Traditional Uvulopatatoplasty (RAUP)
. Myringotomy with effective Hemorrhage « Tumors
Control * Tissue in the Uvula/Soft Palate for the
. Nasal Airway Obstruction by Reduction of Treatment of Snoring
Hypertrophic Nasal Turbinates + — Uvulopatatopharyngoplasty (UPPP)
. Nasopharyngeal / Laryngeat indications . Paratidectomy
including Tracheal Procedures, Laryngeal . Radical Neck Disection
Polypectomy, and Laryngeal Lesion Debulking
. Neck Mass
The Gyrus Somnoplasty TCRF Generator section of the G3 RF Workstation with the
Temperature Controlled Radio-frequency (Somnoplasty®) Electrodes is indicated for
, coagulation of soft tissue including:
The coagulation of enlarged tonsils in patients 13 years of age and older; the reduction of the incidence
of airway obstructions, e.g., base of tongue, soft palate, etc., in patients suffering from UARS or OSAS:
tissue coagulation in the inferior turbinates; and tissue coagulation in the uvula/sott palate which may
reduce the severity of snoring in some individuals.
The system is intended for use by qualified medical personnel trained in the use of electrosurgical
equipment and familiar with potential complications that may arise during or following Head and
Neck surgery.
Contraindications for Use:
There are no known absolute comtraindications to the use of cadio-trequeney surgery. “The use of the Cyrus
G3 Radio-lrequency Workstation is contraindicated when. in the judgement of the Physician, electrosurgical
procedures would be contrary to the best interests of tne patient. ‘The use of the system is alsa
contraindicated for patients with heart pacemakers or other active device implants.
Prescription Use _X OR Over-The-Counter oe ___
(Per 21 CFR 801.109) (Optional Format 1-2-96)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
— oH - IVision Sign:
ess
Division of General, Restorative,
Ay ik
and Neurological Dévices
510(k) Number.AQ//25S7

